Purchase this article with an account.
francesca amoroso, Alexandre PEDINIELLI, Rocio Blanco Garavito, Polina Astroz, Alexandra Miere, Farah Gherdaoui, Eric H Souied; OCTA-guided Navilas therapy for choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 2018;59(9):6198.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the accuracy of the navigated laser photocoagulation system (NAVILAS®, OD-OS GmBH, Teltow, Germany) based on Optical coherence tomography angiography (PlexElite 9000, Carl Zeiss Meditec, Inc., Dublin, USA) for advanced choroidal neovascularization secondary to AMD.
This prospective case-series included seven eyes of seven consecutive patients presented with advanced neovascular AMD. All patients were treated with Navilas using overlaid OCTA images of visible feeder vessel. Inclusion criteria included advanced neovascular membranes with persistance of exsudative signs, no more responsive to anti-VEGF therapy and a BCVA ≤20/400, stable for at least 12 months. Exclusion criteria included prior PDT or laser treatment for AMD. All patients underwent a complete ophtalmic examination in addition to visual acuity assessment, autofluorescence, spectral domain optical coherence tomography, fluorescein angiography, indocyanine green angiography and optical coherence tomography angiography were done at baseline, 1, and 3 months after treatment. Rescue anti-VEGF therapy was performed in non-responsive cases.
Exsudative signs were significantly reduced in all treated patients at 1 and 3 months. Six of the seven treated eyes (86%) presented a rarefaction of vessel density on OCTA at month 1 and 3.There was no changes in best-corrected visual acuity during the follow-up. Rescue anti-VEGF was required only in one eye at 1 months for the appearance of a type 2 neovascularization.
This preliminar study showed that the Navilas treatment based on manually imported OCTA images seems to be accurate and effective in advanced neovascular lesions secondary to AMD. A bigger sample size and a longer follow-up is needed to confirm the efficacy and the long-term safety of this treatment.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only